 low-dose aspirin for primary prevention of cardiovascular disease in adults aged 50 to
59 years who have a 10-year risk of greater than 10% for
cardiovascular disease, have a life expectancy 10 years
or more, and are not at increased risk of bleeding. For individuals aged 60 to 69 years, the decision should be
individualized. There is insufÔ¨Åcient evidence to support
aspirin recommendations for